Strathspey Crown Wins US Patent for Titration of Phenotypic (DNA) Expression
Summary
Strathspey Crown LLC Chairman and lead co-inventor, Robert E. Grant commented, "We are very pleased to expand our intellectual property portfolio in this exciting field with this important and highly attractive commercial sector addressing manipulation of human genetic expression.Titration of phenotypic expression has been referred to as the Holy Grail of the genetic research community and thus may represent a major advance in disease management, lifestyle enhancement and significantly extending life.We strongly believe that precisely targeted sonic wave electromagnetism will eventually provide a fundamental new treatment modality controlling disease predilection and expression."Grant further commented, "This patent is only one within a rapidly expanding IP portfolio at Strathspey Crown that we are confident will have far-reaching ramifications for genetic expression; potentially leading to numerous life-enhancing and life-extending medical applications.Strathspey Crown presently has several other patent applications in pending status with the US Patent and Trademark office, each addressing significant future market segments across medicine, genetic expression, as well as, miniature implantable smart-ocular technologies integrating cameras, an LED display, wireless connectivity and solar recharging ability, including augmented reality-ready ocular implantable technologies."